Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PAVmed Inc.PAVM · Entity 7317 | 10% owner | November 24, 2020 | November 27, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PAVmed Inc.
Report date November 24, 2020 · Filed November 27, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,060,947 |
Reported balance
After 2020-11-24 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2020-11-24 · Sale · Disposed 53,036 · Balance 1,060,947 F1: Securities of PAVmed Inc. (the "Issuer") held directly by the Sirovich Family Charitable Foundation (the "Sirovich Foundation"). Matthew Sirovich is a Director and President of the Sirovich Foundation and may be deemed to beneficially own the securities of the Issuer held by the Sirovich Foundation. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,027,744 |
Reported balance
After 2020-11-25 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2020-11-25 · Sale · Disposed 33,203 · Balance 1,027,744 F1: Securities of PAVmed Inc. (the "Issuer") held directly by the Sirovich Family Charitable Foundation (the "Sirovich Foundation"). Matthew Sirovich is a Director and President of the Sirovich Foundation and may be deemed to beneficially own the securities of the Issuer held by the Sirovich Foundation. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 792,000 |
Reported balance
Holding disclosure · report date 2020-11-24 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 792,000 F2: Securities of the Issuer held directly by The Boomer Fund, L.P. ("Boomer"). Mr. Sirovich is the general partner of Boomer and may be deemed to beneficially own the securities of the Issuer held by Boomer. |
| Common StockSEC Table I · non-derivative | Direct | 1,938,297 |
Reported balance
Holding disclosure · report date 2020-11-24 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,938,297 |
Filing footnotes · ownership attribution and instrument terms
F1: Securities of PAVmed Inc. (the "Issuer") held directly by the Sirovich Family Charitable Foundation (the "Sirovich Foundation"). Matthew Sirovich is a Director and President of the Sirovich Foundation and may be deemed to beneficially own the securities of the Issuer held by the Sirovich Foundation.
F2: Securities of the Issuer held directly by The Boomer Fund, L.P. ("Boomer"). Mr. Sirovich is the general partner of Boomer and may be deemed to beneficially own the securities of the Issuer held by Boomer.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Acorda Therapeutics, Inc.
Report date January 30, 2019 · Filed February 01, 2019
Jointly reported with SCOPIA CAPITAL MANAGEMENT LP, Scopia Management, Inc., MINDICH JEREMY
Section 16 reporting ended · disclosed 2019-02-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 4,750,219 |
Reported balance
After 2019-01-30 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2019-01-30 · Sale · Disposed 7,000 · Balance 4,750,219 F1: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP and Scopia LB LLC (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). Scopia Management, as the investment manager of the Investment Vehicles, F2: (Continued From Footnote 1) may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to the right of an affiliate of Scopia Management to receive performance-based allocations and due to their investments in the Investment Vehicles. F3: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP and Scopia LB LLC (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). Scopia Management, as the investment manager of the Investment Vehicles,
F2: (Continued From Footnote 1) may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to the right of an affiliate of Scopia Management to receive performance-based allocations and due to their investments in the Investment Vehicles.
F3: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
ITRON, INC.
Report date May 28, 2019 · Filed May 30, 2019
Jointly reported with SCOPIA CAPITAL MANAGEMENT LP, Scopia Management, Inc., MINDICH JEREMY
Section 16 reporting ended · disclosed 2019-05-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 3,925,602 |
Reported balance
After 2019-05-28 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2019-05-28 · Sale · Disposed 31,144 · Balance 3,925,602 F1: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by Scopia Capital Management LP ("Scopia Management") on May 20, 2019. F2: Shares of common stock of Itron, Inc. (the "Issuer") that are held in the accounts of several investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia LB LLC, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP and Scopia Long QP LLC (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the Issuer's outstanding shares of common stock. Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. F3: (Continued from footnote 2) In addition, Scopia Management, Inc. ("Scopia Inc."), as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to the right of an affiliate of Scopia Management to receive performance-based allocations and due to their investments in the Investment Vehicles. F4: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities held in the accounts of the Investment Vehicles reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Common StockSEC Table I · non-derivative | Direct | 1,202 |
Reported balance
Holding disclosure · report date 2019-05-28 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,202 F5: Shares of common stock of the Issuer held directly by Matthew Sirovich. |
| Common StockSEC Table I · non-derivative | Direct | 653 |
Reported balance
Holding disclosure · report date 2019-05-28 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 653 F6: Shares of common stock of the Issuer held directly by Jeremy Mindich. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by Scopia Capital Management LP ("Scopia Management") on May 20, 2019.
F2: Shares of common stock of Itron, Inc. (the "Issuer") that are held in the accounts of several investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia LB LLC, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP and Scopia Long QP LLC (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the Issuer's outstanding shares of common stock. Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities.
F3: (Continued from footnote 2) In addition, Scopia Management, Inc. ("Scopia Inc."), as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to the right of an affiliate of Scopia Management to receive performance-based allocations and due to their investments in the Investment Vehicles.
F4: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities held in the accounts of the Investment Vehicles reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
F5: Shares of common stock of the Issuer held directly by Matthew Sirovich.
F6: Shares of common stock of the Issuer held directly by Jeremy Mindich.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 05, 2018 Filed Oct 9, 2018 17:56 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 37,526 | $17.51 | $657,053.99 |
DisclosureSEC source: 0000899243-18-026452 · doc4.xml · nonDerivative · entry 1 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 6,802,061 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP, Scopia LB LLC and Scopia LB International Master Fund LP (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). Scopia Management, as the investment manager of the Investment Vehicles, F2 · ownership.nature: (Continued from Footnote 1) may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to the right of an affiliate of Scopia Management to receive performance-based allocations and due to their investments in the Investment Vehicles. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| October 04, 2018 Filed Oct 4, 2018 18:59 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 37,526 | $18.89 | $708,749.81 |
DisclosureSEC source: 0000899243-18-026245 · doc4.xml · nonDerivative · entry 3 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 6,839,587 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP, Scopia LB LLC and Scopia LB International Master Fund LP (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). Scopia Management, as the investment manager of the Investment Vehicles, F2 · ownership.nature: (Continued from footnote 1) may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to the right of an affiliate of Scopia Management to receive performance-based allocations and due to their investments in the Investment Vehicles. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| October 03, 2018 Filed Oct 4, 2018 18:59 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 56,289 | $19.48 | $1,096,278.94 |
DisclosureSEC source: 0000899243-18-026245 · doc4.xml · nonDerivative · entry 2 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 6,877,113 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP, Scopia LB LLC and Scopia LB International Master Fund LP (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). Scopia Management, as the investment manager of the Investment Vehicles, F2 · ownership.nature: (Continued from footnote 1) may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to the right of an affiliate of Scopia Management to receive performance-based allocations and due to their investments in the Investment Vehicles. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| October 02, 2018 Filed Oct 4, 2018 18:59 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 32,649 | $18.89 | $616,703.70 |
DisclosureSEC source: 0000899243-18-026245 · doc4.xml · nonDerivative · entry 1 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 6,933,402 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP, Scopia LB LLC and Scopia LB International Master Fund LP (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). Scopia Management, as the investment manager of the Investment Vehicles, F2 · ownership.nature: (Continued from footnote 1) may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to the right of an affiliate of Scopia Management to receive performance-based allocations and due to their investments in the Investment Vehicles. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 20:18 UTC | ITRON, INC. ITRI · Entity 2773 | OtherCommon Stock | 162,905 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-18-003640 · doc1.xml · nonDerivative · entry 1 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 5,321,984 F1 · kind: The transaction reported on this Form 4 represents an in-kind pro rata distribution for no consideration of shares of common stock of Itron, Inc. (the "Issuer") by one of the Investment Vehicles (as defined below) to an investor in such Investment Vehicle. None of the Reporting Persons nor any Investment Vehicle retains a pecuniary interest in such shares of common stock of the Issuer. F1 · price: The transaction reported on this Form 4 represents an in-kind pro rata distribution for no consideration of shares of common stock of Itron, Inc. (the "Issuer") by one of the Investment Vehicles (as defined below) to an investor in such Investment Vehicle. None of the Reporting Persons nor any Investment Vehicle retains a pecuniary interest in such shares of common stock of the Issuer. F2 · ownership.nature: Shares of common stock of the Issuer that are held in the accounts of several investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia LB LLC, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia LB International Master Fund LP, Scopia Long International Master Fund LP and Scopia Long QP LLC (together, the "Investment Vehicles") for which Scopia Capital Management LP ("Scopia Management") serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the Issuer's outstanding shares of common stock. Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. F3 · ownership.nature: (continued from Footnote 2) In addition, Scopia Management, Inc. ("Scopia Inc."), as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to the right of an affiliate of Scopia Management to receive performance-based allocations and due to their investments in the Investment Vehicles. F4 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 16:15 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | OtherCommon Stock | 140,904 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-18-003636 · doc1.xml · nonDerivative · entry 1 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 6,966,051 F1 · kind: The transaction reported on this Form 4 represents an in-kind pro rata distribution for no consideration of shares of common stock of Acorda Therapeutics, Inc. (the "Issuer") by one of the Investment Vehicles (as defined below) to an investor in such Investment Vehicle. None of the Reporting Persons nor any Investment Vehicle retains a pecuniary interest in such shares of common stock of the Issuer. F1 · price: The transaction reported on this Form 4 represents an in-kind pro rata distribution for no consideration of shares of common stock of Acorda Therapeutics, Inc. (the "Issuer") by one of the Investment Vehicles (as defined below) to an investor in such Investment Vehicle. None of the Reporting Persons nor any Investment Vehicle retains a pecuniary interest in such shares of common stock of the Issuer. F2 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP, Scopia LB LLC and Scopia LB International Master Fund LP (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of the Issuer. Scopia Management, as the investment manager of the Investment Vehicles, F3 · ownership.nature: (continued from Footnote 2) may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to the right of an affiliate of Scopia Management to receive performance-based allocations and due to their investments in the Investment Vehicles. F4 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| September 06, 2018 Filed Sep 6, 2018 16:14 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 13,829 | $27.82 | $384,682.68 |
DisclosureSEC source: 0000891092-18-006451 · e2086_4.xml · nonDerivative · entry 3 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 7,106,955 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP, Scopia LB LLC and Scopia LB International Master Fund LP (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). F2 · ownership.nature: (Continued from Footnote 1) Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to Scopia Management's right to receive performance-based allocations. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 16:14 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 200 | $29.00 | $5,800.00 |
DisclosureSEC source: 0000891092-18-006451 · e2086_4.xml · nonDerivative · entry 2 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 7,120,784 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP, Scopia LB LLC and Scopia LB International Master Fund LP (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). F2 · ownership.nature: (Continued from Footnote 1) Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to Scopia Management's right to receive performance-based allocations. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| August 28, 2018 Filed Sep 6, 2018 16:14 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 20,256 | $29.41 | $595,658.06 |
DisclosureSEC source: 0000891092-18-006451 · e2086_4.xml · nonDerivative · entry 1 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 7,120,984 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP, Scopia LB LLC and Scopia LB International Master Fund LP (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). F2 · ownership.nature: (Continued from Footnote 1) Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to Scopia Management's right to receive performance-based allocations. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| July 25, 2018 Filed Jul 25, 2018 17:20 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 11,551 | $28.89 | $333,740.73 |
DisclosureSEC source: 0000891092-18-005444 · e1530_4.xml · nonDerivative · entry 3 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 7,141,240 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP, Scopia LB LLC and Scopia LB International Master Fund LP (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). F2 · ownership.nature: (Continued from Footnote 1) Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to Scopia Management's right to receive performance-based allocations. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| July 24, 2018 Filed Jul 25, 2018 17:20 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 50,000 | $28.69 | $1,434,550.00 |
DisclosureSEC source: 0000891092-18-005444 · e1530_4.xml · nonDerivative · entry 2 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 7,152,791 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP, Scopia LB LLC and Scopia LB International Master Fund LP (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). F2 · ownership.nature: (Continued from Footnote 1) Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to Scopia Management's right to receive performance-based allocations. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| July 23, 2018 Filed Jul 25, 2018 17:20 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 25,000 | $28.32 | $708,025.00 |
DisclosureSEC source: 0000891092-18-005444 · e1530_4.xml · nonDerivative · entry 1 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 7,202,791 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP, Scopia LB LLC and Scopia LB International Master Fund LP (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). F2 · ownership.nature: (Continued from Footnote 1) Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to Scopia Management's right to receive performance-based allocations. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| July 20, 2018 Filed Jul 20, 2018 16:43 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 21,580 | $29.05 | $626,894.68 |
DisclosureSEC source: 0000891092-18-005399 · e1505_4.xml · nonDerivative · entry 3 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 7,227,791 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP, Scopia LB LLC and Scopia LB International Master Fund LP (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). F2 · ownership.nature: (Continued from Footnote 1) Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to Scopia Management's right to receive performance-based allocations. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| July 19, 2018 Filed Jul 20, 2018 16:43 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 65,700 | $29.15 | $1,914,859.35 |
DisclosureSEC source: 0000891092-18-005399 · e1505_4.xml · nonDerivative · entry 2 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 7,249,371 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP, Scopia LB LLC and Scopia LB International Master Fund LP (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). F2 · ownership.nature: (Continued from Footnote 1) Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to Scopia Management's right to receive performance-based allocations. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| July 18, 2018 Filed Jul 20, 2018 16:43 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 21,460 | $28.97 | $621,732.68 |
DisclosureSEC source: 0000891092-18-005399 · e1505_4.xml · nonDerivative · entry 1 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 7,315,071 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP, Scopia LB LLC and Scopia LB International Master Fund LP (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). F2 · ownership.nature: (Continued from Footnote 1) Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to Scopia Management's right to receive performance-based allocations. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| July 17, 2018 Filed Jul 17, 2018 17:22 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 8,199 | $30.05 | $246,353.71 |
DisclosureSEC source: 0000891092-18-005342 · e1153_4.xml · nonDerivative · entry 3 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 7,336,531 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP, Scopia LB LLC, Scopia LB International Master Fund LP and a certain managed account (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). F2 · ownership.nature: (Continued from Footnote 1) Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to Scopia Management's right to receive performance-based allocations. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| July 16, 2018 Filed Jul 17, 2018 17:22 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 25,000 | $30.04 | $750,977.50 |
DisclosureSEC source: 0000891092-18-005342 · e1153_4.xml · nonDerivative · entry 2 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 7,344,730 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP, Scopia LB LLC, Scopia LB International Master Fund LP and a certain managed account (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). F2 · ownership.nature: (Continued from Footnote 1) Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to Scopia Management's right to receive performance-based allocations. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| July 13, 2018 Filed Jul 17, 2018 17:22 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 100 | $30.00 | $3,000.00 |
DisclosureSEC source: 0000891092-18-005342 · e1153_4.xml · nonDerivative · entry 1 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 7,369,730 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP, Scopia LB LLC, Scopia LB International Master Fund LP and a certain managed account (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). F2 · ownership.nature: (Continued from Footnote 1) Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to Scopia Management's right to receive performance-based allocations. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| July 10, 2018 Filed Jul 10, 2018 17:13 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 8,226 | $30.27 | $248,980.46 |
DisclosureSEC source: 0000891092-18-005253 · e1110_4.xml · nonDerivative · entry 3 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 7,369,830 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP, Scopia LB LLC, Scopia LB International Master Fund LP and a certain managed account (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). F2 · ownership.nature: (Continued from Footnote 1) Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to Scopia Management's right to receive performance-based allocations. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| July 09, 2018 Filed Jul 10, 2018 17:13 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 32,128 | $30.27 | $972,549.90 |
DisclosureSEC source: 0000891092-18-005253 · e1110_4.xml · nonDerivative · entry 2 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 7,378,056 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP, Scopia LB LLC, Scopia LB International Master Fund LP and a certain managed account (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). F2 · ownership.nature: (Continued from Footnote 1) Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to Scopia Management's right to receive performance-based allocations. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| July 06, 2018 Filed Jul 10, 2018 17:13 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 160,000 | $30.70 | $4,911,264.00 |
DisclosureSEC source: 0000891092-18-005253 · e1110_4.xml · nonDerivative · entry 1 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 7,410,184 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP, Scopia LB LLC, Scopia LB International Master Fund LP and a certain managed account (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). F2 · ownership.nature: (Continued from Footnote 1) Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to Scopia Management's right to receive performance-based allocations. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| July 05, 2018 Filed Jul 5, 2018 17:23 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 27,093 | $30.10 | $815,380.09 |
DisclosureSEC source: 0000891092-18-005200 · e79195_4.xml · nonDerivative · entry 3 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 7,570,184 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP, Scopia LB LLC, Scopia LB International Master Fund LP and a certain managed account (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). F2 · ownership.nature: (Continued from Footnote 1) Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to Scopia Management's right to receive performance-based allocations. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| July 03, 2018 Filed Jul 5, 2018 17:23 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 3,400 | $30.01 | $102,049.98 |
DisclosureSEC source: 0000891092-18-005200 · e79195_4.xml · nonDerivative · entry 2 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 7,597,277 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP, Scopia LB LLC, Scopia LB International Master Fund LP and a certain managed account (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). F2 · ownership.nature: (Continued from Footnote 1) Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to Scopia Management's right to receive performance-based allocations. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 17:23 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 35,889 | $30.06 | $1,078,870.00 |
DisclosureSEC source: 0000891092-18-005200 · e79195_4.xml · nonDerivative · entry 1 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 7,600,677 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP, Scopia LB LLC, Scopia LB International Master Fund LP and a certain managed account (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). F2 · ownership.nature: (Continued from Footnote 1) Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to Scopia Management's right to receive performance-based allocations. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| June 21, 2018 Filed Jun 25, 2018 18:39 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 60,295 | $30.53 | $1,840,649.58 |
DisclosureSEC source: 0000899243-18-017979 · doc4.xml · nonDerivative · entry 1 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 7,636,566 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP, Scopia LB LLC, Scopia LB International Master Fund LP and a certain managed account (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). F2 · ownership.nature: (Continued from Footnote 1) Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to Scopia Management's right to receive performance-based allocations. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| June 20, 2018 Filed Jun 20, 2018 20:09 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 58,700 | $30.37 | $1,782,595.73 |
DisclosureSEC source: 0000899243-18-017470 · doc4.xml · nonDerivative · entry 3 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 7,696,861 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP, Scopia LB LLC, Scopia LB International Master Fund LP and a certain managed account (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). F2 · ownership.nature: (Continued from Footnote 1) Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to Scopia Management's right to receive performance-based allocations. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| June 19, 2018 Filed Jun 20, 2018 20:09 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 91,070 | $30.63 | $2,789,091.61 |
DisclosureSEC source: 0000899243-18-017470 · doc4.xml · nonDerivative · entry 2 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 7,755,561 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP, Scopia LB LLC, Scopia LB International Master Fund LP and a certain managed account (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). F2 · ownership.nature: (Continued from Footnote 1) Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to Scopia Management's right to receive performance-based allocations. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| June 18, 2018 Filed Jun 20, 2018 20:09 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 243,414 | $30.77 | $7,490,919.80 |
DisclosureSEC source: 0000899243-18-017470 · doc4.xml · nonDerivative · entry 1 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 7,846,631 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP, Scopia LB LLC, Scopia LB International Master Fund LP and a certain managed account (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). F2 · ownership.nature: (Continued from Footnote 1) Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to Scopia Management's right to receive performance-based allocations. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| June 15, 2018 Filed Jun 15, 2018 20:18 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 29,114 | $31.50 | $917,117.20 |
DisclosureSEC source: 0000899243-18-016863 · doc4.xml · nonDerivative · entry 3 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 8,090,045 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP, Scopia LB LLC, Scopia LB International Master Fund LP and a certain managed account (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). F2 · ownership.nature: (Continued from Footnote 1) Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to Scopia Management's right to receive performance-based allocations. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| June 14, 2018 Filed Jun 15, 2018 20:18 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 87,796 | $31.54 | $2,769,278.99 |
DisclosureSEC source: 0000899243-18-016863 · doc4.xml · nonDerivative · entry 2 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 8,119,159 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP, Scopia LB LLC, Scopia LB International Master Fund LP and a certain managed account (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). F2 · ownership.nature: (Continued from Footnote 1) Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to Scopia Management's right to receive performance-based allocations. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 20:18 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 100,000 | $31.71 | $3,171,260.00 |
DisclosureSEC source: 0000899243-18-016863 · doc4.xml · nonDerivative · entry 1 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 8,206,955 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP, Scopia LB LLC, Scopia LB International Master Fund LP and a certain managed account (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). F2 · ownership.nature: (Continued from Footnote 1) Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to Scopia Management's right to receive performance-based allocations. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| June 12, 2018 Filed Jun 12, 2018 20:46 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 53,600 | $31.58 | $1,692,655.84 |
DisclosureSEC source: 0000899243-18-016288 · doc4.xml · nonDerivative · entry 2 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 8,306,955 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP, Scopia LB LLC, Scopia LB International Master Fund LP and a certain managed account (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). Scopia Management, as the investment manager of the Investment Vehicles, F2 · ownership.nature: (Continued from Footnote 1) may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to Scopia Management's right to receive performance-based allocations. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| June 08, 2018 Filed Jun 12, 2018 20:46 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 114,173 | $31.13 | $3,553,805.88 |
DisclosureSEC source: 0000899243-18-016288 · doc4.xml · nonDerivative · entry 1 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 8,360,555 F1 · ownership.nature: This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP, Scopia LB LLC, Scopia LB International Master Fund LP and a certain managed account (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). Scopia Management, as the investment manager of the Investment Vehicles, F2 · ownership.nature: (Continued from Footnote 1) may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to Scopia Management's right to receive performance-based allocations. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| May 24, 2018 Filed May 29, 2018 20:06 UTC | ITRON, INC. ITRI · Entity 2773 | PurchaseCommon Stock | 20,000 | $59.43 | $1,188,672.00 |
DisclosureSEC source: 0001140361-18-025983 · doc1.xml · nonDerivative · entry 1 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 5,484,889 F1 · ownership.nature: Shares of common stock of Itron, Inc. (the "Issuer") that are held in the accounts of several investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia LB LLC, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia LB International Master Fund LP, Scopia Long International Master Fund LP and Scopia Long QP LLC, and a certain managed account (together, the "Investment Vehicles") for which Scopia Capital Management LP ("Scopia Management") serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the Issuer's outstanding shares of common stock. Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. F2 · ownership.nature: (continued from Footnote 1) In addition, Scopia Management, Inc. ("Scopia Inc."), as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to Scopia Management's right to receive performance-based allocations. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| May 23, 2018 Filed May 24, 2018 20:09 UTC | ITRON, INC. ITRI · Entity 2773 | PurchaseCommon Stock | 50,000 | $59.57 | $2,978,255.00 |
DisclosureSEC source: 0001140361-18-025505 · doc1.xml · nonDerivative · entry 2 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 5,464,889 F1 · ownership.nature: Shares of common stock of Itron, Inc. (the "Issuer") that are held in the accounts of several investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia LB LLC, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia LB International Master Fund LP, Scopia Long International Master Fund LP and Scopia Long QP LLC, and a certain managed account (together, the "Investment Vehicles") for which Scopia Capital Management LP ("Scopia Management") serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the Issuer's outstanding shares of common stock. Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. F2 · ownership.nature: (continued from Footnote 1) In addition, Scopia Management, Inc. ("Scopia Inc."), as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to Scopia Management's right to receive performance-based allocations. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| May 22, 2018 Filed May 24, 2018 20:09 UTC | ITRON, INC. ITRI · Entity 2773 | PurchaseCommon Stock | 78,620 | $59.72 | $4,694,816.89 |
DisclosureSEC source: 0001140361-18-025505 · doc1.xml · nonDerivative · entry 1 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 5,414,889 F1 · ownership.nature: Shares of common stock of Itron, Inc. (the "Issuer") that are held in the accounts of several investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia LB LLC, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia LB International Master Fund LP, Scopia Long International Master Fund LP and Scopia Long QP LLC, and a certain managed account (together, the "Investment Vehicles") for which Scopia Capital Management LP ("Scopia Management") serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the Issuer's outstanding shares of common stock. Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. F2 · ownership.nature: (continued from Footnote 1) In addition, Scopia Management, Inc. ("Scopia Inc."), as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to Scopia Management's right to receive performance-based allocations. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| May 21, 2018 Filed May 22, 2018 20:10 UTC | ITRON, INC. ITRI · Entity 2773 | PurchaseCommon Stock | 75,000 | $59.84 | $4,488,225.00 |
DisclosureSEC source: 0001140361-18-025177 · doc1.xml · nonDerivative · entry 2 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 5,336,269 F1 · ownership.nature: Shares of common stock of Itron, Inc. (the "Issuer") that are held in the accounts of several investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia LB LLC, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia LB International Master Fund LP, Scopia Long International Master Fund LP and Scopia Long QP LLC, and a certain managed account (together, the "Investment Vehicles") for which Scopia Capital Management LP ("Scopia Management") serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the Issuer's outstanding shares of common stock. Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. F2 · ownership.nature: (continued from Footnote 1) In addition, Scopia Management, Inc. ("Scopia Inc."), as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to Scopia Management's right to receive performance-based allocations. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| May 18, 2018 Filed May 22, 2018 20:10 UTC | ITRON, INC. ITRI · Entity 2773 | PurchaseCommon Stock | 39,129 | $58.36 | $2,283,681.91 |
DisclosureSEC source: 0001140361-18-025177 · doc1.xml · nonDerivative · entry 1 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 5,261,269 F1 · ownership.nature: Shares of common stock of Itron, Inc. (the "Issuer") that are held in the accounts of several investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia LB LLC, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia LB International Master Fund LP, Scopia Long International Master Fund LP and Scopia Long QP LLC, and a certain managed account (together, the "Investment Vehicles") for which Scopia Capital Management LP ("Scopia Management") serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the Issuer's outstanding shares of common stock. Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. F2 · ownership.nature: (continued from Footnote 1) In addition, Scopia Management, Inc. ("Scopia Inc."), as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to Scopia Management's right to receive performance-based allocations. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 21:21 UTC | ITRON, INC. ITRI · Entity 2773 | PurchaseCommon Stock | 8,370 | $68.66 | $574,700.94 |
DisclosureSEC source: 0000899243-18-000268 · doc4.xml · nonDerivative · entry 2 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,222,140 F1 · kind: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Scopia Capital Management LP ("Scopia Management") on December 8, 2017. F2 · ownership.nature: Shares of common stock of Itron, Inc. (the "Issuer") that are held in the accounts of several investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia LB LLC, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia LB International Master Fund LP, Scopia Long International Master Fund LP and Scopia Long QP LLC, and a certain managed account (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the Issuer's outstanding shares of common stock. Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. F3 · ownership.nature: (Continued from footnote 2) In addition, Scopia Management, Inc. ("Scopia Inc."), as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to Scopia Management's right to receive performance-based allocations. F4 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 29, 2017 Filed Jan 3, 2018 21:21 UTC | ITRON, INC. ITRI · Entity 2773 | PurchaseCommon Stock | 13,500 | $68.56 | $925,492.50 |
DisclosureSEC source: 0000899243-18-000268 · doc4.xml · nonDerivative · entry 1 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,213,770 F1 · kind: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Scopia Capital Management LP ("Scopia Management") on December 8, 2017. F2 · ownership.nature: Shares of common stock of Itron, Inc. (the "Issuer") that are held in the accounts of several investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia LB LLC, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia LB International Master Fund LP, Scopia Long International Master Fund LP and Scopia Long QP LLC, and a certain managed account (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the Issuer's outstanding shares of common stock. Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. F3 · ownership.nature: (Continued from footnote 2) In addition, Scopia Management, Inc. ("Scopia Inc."), as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to Scopia Management's right to receive performance-based allocations. F4 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 28, 2017 Filed Dec 29, 2017 21:22 UTC | ITRON, INC. ITRI · Entity 2773 | PurchaseCommon Stock | 12,421 | $68.14 | $846,409.17 |
DisclosureSEC source: 0000899243-17-029727 · doc4.xml · nonDerivative · entry 2 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,200,270 F1 · kind: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Scopia Capital Management LP ("Scopia Management") on December 8, 2017. F2 · ownership.nature: Shares of common stock of Itron, Inc. (the "Issuer") that are held in the accounts of several investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia LB LLC, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia LB International Master Fund LP, Scopia Long International Master Fund LP and Scopia Long QP LLC, and a certain managed account (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the Issuer's outstanding shares of common stock. Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. F3 · ownership.nature: (Continued from footnote 2) In addition, Scopia Management, Inc. ("Scopia Inc."), as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to Scopia Management's right to receive performance-based allocations. F4 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 27, 2017 Filed Dec 29, 2017 21:22 UTC | ITRON, INC. ITRI · Entity 2773 | PurchaseCommon Stock | 11,315 | $68.02 | $769,663.27 |
DisclosureSEC source: 0000899243-17-029727 · doc4.xml · nonDerivative · entry 1 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,187,849 F1 · kind: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Scopia Capital Management LP ("Scopia Management") on December 8, 2017. F2 · ownership.nature: Shares of common stock of Itron, Inc. (the "Issuer") that are held in the accounts of several investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia LB LLC, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia LB International Master Fund LP, Scopia Long International Master Fund LP and Scopia Long QP LLC, and a certain managed account (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the Issuer's outstanding shares of common stock. Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. F3 · ownership.nature: (Continued from footnote 2) In addition, Scopia Management, Inc. ("Scopia Inc."), as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to Scopia Management's right to receive performance-based allocations. F4 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 26, 2017 Filed Dec 27, 2017 21:17 UTC | ITRON, INC. ITRI · Entity 2773 | PurchaseCommon Stock | 14,899 | $67.68 | $1,008,417.96 |
DisclosureSEC source: 0000899243-17-029617 · doc4.xml · nonDerivative · entry 2 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,176,534 F1 · kind: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Scopia Capital Management LP ("Scopia Management") on December 8, 2017. F2 · ownership.nature: Shares of common stock of Itron, Inc. (the "Issuer") that are held in the accounts of several investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia LB LLC, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia LB International Master Fund LP, Scopia Long International Master Fund LP and Scopia Long QP LLC, and a certain managed account (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the Issuer's outstanding shares of common stock. Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. F3 · ownership.nature: (Continued from Footnote 2) In addition, Scopia Management, Inc. ("Scopia Inc."), as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to Scopia Management's right to receive performance-based allocations. F4 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 22, 2017 Filed Dec 27, 2017 21:17 UTC | ITRON, INC. ITRI · Entity 2773 | PurchaseCommon Stock | 6,930 | $68.40 | $473,998.83 |
DisclosureSEC source: 0000899243-17-029617 · doc4.xml · nonDerivative · entry 1 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,161,635 F1 · kind: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Scopia Capital Management LP ("Scopia Management") on December 8, 2017. F2 · ownership.nature: Shares of common stock of Itron, Inc. (the "Issuer") that are held in the accounts of several investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia LB LLC, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia LB International Master Fund LP, Scopia Long International Master Fund LP and Scopia Long QP LLC, and a certain managed account (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the Issuer's outstanding shares of common stock. Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. F3 · ownership.nature: (Continued from Footnote 2) In addition, Scopia Management, Inc. ("Scopia Inc."), as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to Scopia Management's right to receive performance-based allocations. F4 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 21, 2017 Filed Dec 22, 2017 21:13 UTC | ITRON, INC. ITRI · Entity 2773 | PurchaseCommon Stock | 22,024 | $69.80 | $1,537,244.37 |
DisclosureSEC source: 0000899243-17-029467 · doc4.xml · nonDerivative · entry 2 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,154,705 F1 · kind: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Scopia Capital Management LP ("Scopia Management") on December 8, 2017. F2 · ownership.nature: Shares of common stock of Itron, Inc. (the "Issuer") that are held in the accounts of several investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia LB LLC, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia LB International Master Fund LP, Scopia Long International Master Fund LP and Scopia Long QP LLC, and a certain managed account (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the Issuer's outstanding shares of common stock. Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. F3 · ownership.nature: (Continued from Footnote 2) In addition, Scopia Management, Inc. ("Scopia Inc."), as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to Scopia Management's right to receive performance-based allocations. F4 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 20, 2017 Filed Dec 22, 2017 21:13 UTC | ITRON, INC. ITRI · Entity 2773 | PurchaseCommon Stock | 16,901 | $68.98 | $1,165,793.80 |
DisclosureSEC source: 0000899243-17-029467 · doc4.xml · nonDerivative · entry 1 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,132,681 F1 · kind: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Scopia Capital Management LP ("Scopia Management") on December 8, 2017. F2 · ownership.nature: Shares of common stock of Itron, Inc. (the "Issuer") that are held in the accounts of several investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia LB LLC, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia LB International Master Fund LP, Scopia Long International Master Fund LP and Scopia Long QP LLC, and a certain managed account (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the Issuer's outstanding shares of common stock. Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. F3 · ownership.nature: (Continued from Footnote 2) In addition, Scopia Management, Inc. ("Scopia Inc."), as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to Scopia Management's right to receive performance-based allocations. F4 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 14, 2017 Filed Dec 18, 2017 23:44 UTC | ITRON, INC. ITRI · Entity 2773 | PurchaseCommon Stock | 2,160 | $69.91 | $150,999.98 |
DisclosureSEC source: 0000899243-17-029071 · doc4.xml · nonDerivative · entry 1 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,115,780 F1 · kind: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Scopia Capital Management LP ("Scopia Management") on December 8, 2017. F2 · ownership.nature: Shares of common stock of Itron, Inc. (the "Issuer") that are held in the accounts of several investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia LB LLC, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia LB International Master Fund LP, Scopia Long International Master Fund LP and Scopia Long QP LLC, and a certain managed account (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the Issuer's outstanding shares of common stock. Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. F3 · ownership.nature: (Continued from Footnote 2) In addition, Scopia Management, Inc. ("Scopia Inc."), as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to Scopia Management's right to receive performance-based allocations. F4 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 12, 2017 Filed Dec 13, 2017 21:16 UTC | ITRON, INC. ITRI · Entity 2773 | PurchaseCommon Stock | 1,497 | $69.92 | $104,668.29 |
DisclosureSEC source: 0000899243-17-028610 · doc4.xml · nonDerivative · entry 2 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,113,620 F1 · kind: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Scopia Capital Management LP ("Scopia Management") on December 8, 2017. F2 · ownership.nature: Shares of common stock of Itron, Inc. (the "Issuer") that are held in the accounts of several investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia LB LLC, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia LB International Master Fund LP, Scopia Long International Master Fund LP and Scopia Long QP LLC, and a certain managed account (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the Issuer's outstanding shares of common stock. Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. F3 · ownership.nature: (continued from footnote 2) In addition, Scopia Management, Inc. ("Scopia Inc."), as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to Scopia Management's right to receive performance-based allocations. F4 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 21:16 UTC | ITRON, INC. ITRI · Entity 2773 | PurchaseCommon Stock | 11,983 | $69.25 | $829,807.17 |
DisclosureSEC source: 0000899243-17-028610 · doc4.xml · nonDerivative · entry 1 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,112,123 F1 · kind: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Scopia Capital Management LP ("Scopia Management") on December 8, 2017. F2 · ownership.nature: Shares of common stock of Itron, Inc. (the "Issuer") that are held in the accounts of several investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia LB LLC, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia LB International Master Fund LP, Scopia Long International Master Fund LP and Scopia Long QP LLC, and a certain managed account (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the Issuer's outstanding shares of common stock. Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. F3 · ownership.nature: (continued from footnote 2) In addition, Scopia Management, Inc. ("Scopia Inc."), as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to Scopia Management's right to receive performance-based allocations. F4 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 08, 2017 Filed Dec 8, 2017 21:43 UTC | ITRON, INC. ITRI · Entity 2773 | PurchaseCommon Stock | 6,700 | $68.93 | $461,797.50 |
DisclosureSEC source: 0001140361-17-045486 · doc1.xml · nonDerivative · entry 8 SCOPIA CAPITAL MANAGEMENT LP · CIK 0001279150 · 10% owner Scopia Management, Inc. · CIK 0001665995 · 10% owner SIROVICH MATTHEW · CIK 0001431208 · 10% owner MINDICH JEREMY · CIK 0001431207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 5,100,140 F1 · ownership.nature: Shares of common stock of Itron, Inc. (the "Issuer") that are held in the accounts of several investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia LB LLC, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia LB International Master Fund LP, Scopia Long International Master Fund LP and Scopia Long QP LLC, and a certain managed account (together, the "Investment Vehicles") for which Scopia Capital Management LP ("Scopia Management") serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the Issuer's outstanding shares of common stock. Scopia Management, as the investment manager of the Investment Vehicles, may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. F2 · ownership.nature: (continued from Footnote 1) In addition, Scopia Management, Inc. ("Scopia Inc."), as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to Scopia Management's right to receive performance-based allocations. F3 · ownership.nature: Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.